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Abstract
Background: The efficiency of antiretroviral therapy (ART) depends on a near perfect level of patients’ adherence.
The level of adherence of adults HIV-infected patients treated in the HIV/AIDS health care centres of the
association “Espoir Vie Togo” in Togo, West Africa is not properly documented. The aim of the present study was
to examine by means of self-reports the knowledge, the adherence level and associated factors to antiretroviral
therapy (ART) among these patients.
Methods: We conducted a cross-sectional survey among adult people living with HIV/AIDS (PLWHA) through a
structured questionnaire.
Results: A total of 99 patients were enrolled. Among them, 55.6% knew the name of antiretroviral agents of
regimens prescribed. All patients had a good knowledge of treatment schedule. The treatment regimens based on
2 NRTIs + 1 NNRTI were used in 90% of patients. The average adherence rate was 89.8% of the total doses
prescribed while 62.62% of patients showed an adherence rate of 95% or above. The treated groups were similar
in term of median % of medication doses taken according to PLWHA epidemiological characteristics. However,
patients reported forgetting (34.9%), travel (25.6%), cost of treatment (13.9%) and side effects (11.6%) as the main
factors of missing at least once a dose intake.
Conclusion: These results should encourage the association and all the involved actors in the HIV/AIDS’s program
to strengthen counseling, education and information interventions for HIV-infected patients in order to overcome
the potential barriers of poor adherence.
Background
Since 1996, progress in the field of antiretroviral therapy
has led to the reduction of about 80% of deaths, the
number of cases of acquired immunodeficiency syn-
drome (AIDS) and the incidence of opportunistic infec-
tions [1]. About twenty drugs belonging to 4 classes
defined according to their pharmacological modes of
action constitute the current arsenal of antiretroviral
drugs (ARVs). The combinations of these drugs have
dramatically changed the prognosis of an infection
which natural consequence is death for over 90% of the
patients into chronic infection [2,3]. The long-term nat-
ure of the disease has further complicated its manage-
ment. In this context, sustained adherence is an
essential tool of the long-term efficiency of ARVs ther-
apy [4] (e.g. significant reduction in viral load, drug
resistance, deterioration of health status and treatment
failure) [5-8]. In addition, the role of the knowledge of
treatment regimens [9] and cognitive demands related
t ot h ec o m p l e x i t yo fA R V sp h a r m a c o t h e r a p y[ 1 0 , 1 1 ]
were reported as factors that may influence the level of
adherence [12,13]. Recent studies on patients’ adherence
in African health contexts showed that it is relatively * Correspondence: ypotchoo@hotmail.com
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text [14,15].
Cohorts followed up in developed countries have
emphasized the frequency of non-adherence situations,
the high level of adherence required to obtain optimal
efficiency of ARVs chemotherapy, and delay the begin-
ning of the human immunodeficiency virus (HIV) resis-
tance and pejorative evolution of the disease [6,16].
The assessment of adherence, parameter that has no
standard method of measurement, which varies over
time, meets a number of methodological difficulties [5].
Few studies have documented the factors involved and
the level of adherence of adults people living with HIV/
AIDS (PLWHA) to ARVs therapy in Togo, West Africa.
T h eo b j e c t i v e so ft h ep r e s e n ts t u d yw e r et oa s s e s st h e
knowledge of the treatment regimens prescribed to
patients; quantify the level of adherence to ARVs ther-
apy and identify the factors related to non-adherence.
Eligible patients and method
T h ep r e s e n ts t u d yw a sac r o s s -sectional survey carried
out during the months of August and October 2005 in
the HIV/AIDS health care centers (in urban areas of
Lomé and Sokodé) of the association “Espoir Vie Togo”
(EVT), the first organized non-governmental organiza-
tion of people living with HIV/AIDS and those contri-
buting to their support. The association is recognized by
National HIV/AIDS Control Programme “Programme
National de Lutte contre le SIDA” (PNLS-Togo) as an
ambulatory HIV/AIDS health care association. The asso-
ciation is also involved in the purchasing of ARVs for its
members from the “Centrale d’Achat de Médicaments
Essentiels et Génériques” (CAMEG-Togo). The ARVs
are supplied to the patients, in EVT’s pharmaceutical
stores.
We interviewed eligible HIV-infected adults when they
came to EVT’s pharmaceutical stores to receive their
monthly supply of ARVs. The enrolment was done on a
voluntary basis.
Inclusion criteria
To be enrolled in the study, HIV-infected patients have
to meet the following criteria: all adult patients over 15
years, the members of EVT association placed on ARVs
therapy for over 1 month, who receive ARVs in EVT
pharmaceutical stores. Hospitalized patients and those
whose age is below 15 years were excluded from the
study.
Data collection method and variable of interest
A cross-sectional survey was conducted from a struc-
tured questionnaire (additional file 1) submitted to
enrolled patients (face-to-face interviews for about 30-45
mn). The relevant data were collected for a period
covering one month per EVT’s health care centre
(August and October 2005). Data collected concerned
the following variables:
- The characteristics of patients (sex, age, educational
level) and ARVs procurement;
- The patient treatment knowledge which was assessed
through the knowledge of the names of the various
drugs prescribed their respective dosages (number of
tablets per dose and number of daily intakes) and the
times of intake. The statements of patients were com-
pared with the prescriptions and the treatment regimens
mentioned in their health card;
-The type of ARVs combination regimens prescribed;
- The rate of adherence to treatment by means of self-
reporting: It was assessed in the last month and defined
as the number of doses taken during the last 7 days
before each interview. Adherence score was expressed as
the proportion (%) of tablets taken compared to pre-
scribed tablets. An adherence rate of 95% or more was
considered to be good.
-The factors that induced poor adherence to
treatment.
Given that the Ethic Committee was not available at
the period of the study, the Ministry of the Health
authorized the survey.
Statistical analyses
The median % of medication doses taken by treated
groups were compared using ANOVA method (Sigma
Stat32 software; Jandal Corp, San Rafael, CA): t test was
used for the sex factor; Mann-Whitney Rank sum test
was used for the ARVs procurement and the ARVs
combination prescribed and Kruskal-Wallis one-way
analysis of variance on ranks method was used for the
a g eg r o u p sa n dt h ee d u c a t i o n a ll e v e l .T h ed i f f e r e n c e
between the groups was considered to be significant if
p < 0.05.
Results
A total of 99 patients (77.3%) of 128 interviewed during
the investigation, accepted to be submitted to the
questionnaire.
Sex and age of patients
Of the total sample (n = 99), 76 were female (76.8%)
and 23 male (23.2%) with a sex ratio of 0.3. The age of
patients ranged between 21 to 57 years, with an average
age of 36.8 years. The age group from 36 to 45 years
was more representative (39.4%), followed by 26 to
35 years (34.3%).
ARVs procurement
Among the patients included in this study, sixty one
percent were under an individual financial participation
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reduced to US $ 2 since November 2005), the remaining
received ARVs free of charge.
Treatment regimen knowledge
Forty four patients (44.4%), knew perfectly the names of
various ARVs included in the combination regimens. All
respondents had a perfect knowledge of the treatment
schedule (number of tablets per dose, the number of
daily intakes and the times of drug intake).
Types of ARVs combinations prescribed
All patients have received a combination of three ARVs.
Four different ARVs combinations (ARVs-GF (Global
Fund)) were legalized, of which one available fixed-dose
combination (lamivudine + stavudine + nevirapine).
Only 39.4% of patients have received this fixed-dose
combination as against 60.6% who were placed on non-
fixed-dose combinations.
The treatment regimen containing 2 nucleoside
reverse transcriptase inhibitors (NRTIs) + 1 non-nucleo-
side reverse transcriptase inhibitor (NNRTI) was used in
89.9% of patients; While the remaining 10.1% were
placed on 2 NRTIs + 1 protease inhibitor (PI) based
regimens (Figure 1).
Adherence rate to ARVs therapy
The average individual adherence level was 89.8% of
doses taken while sixty two (62) patients (62.62%)
reported 95% or more of the doses taken. Table 1 shows
the distribution of median % of medication doses taken
according to the PLWHA epidemiological characteristics
and P values. Except patients group who received 2
NRTIs + 1 PI combination (median percent of 46% of
doses taken), the median percent of other treated groups
varied from 82% to 92% of doses prescribed.
Factors of non-adherence
Forgetting (34.9%), travel (25.6%), cost of treatment
(13.9%) and side effects (11.6%) were the main factors of
poor adherence reported by the 43 patients who missed
a tl e a s to n c ead o s ei n t a k e( F i g u r e2 ) .T h e yr e p o r t e d
using a method in order not to forget the medication
intake. Among them 69.4% stated using a watch and/or
an alarm clock to remember the time of drug intake,
while 27.9% referred to parents’ recall for the medica-
tion intake.
Twelve patients (12.1%) stopped or changed one or
more ARVs included in the treatment regimens because
of side effects in 6 patients (6.1%), inefficiency in
4 patients (4%) and because of disease in 2 patients (2%).
Discussion
The assessment of the adherence level by interviewing
PLWHA seems to be an acceptable method in Africa. It
is simple, cheap and accessible. This method has, how-
ever some limits (the length of interview, the subjectivity
of patient statements). The fact that the investigator is
unknown to the patients, that he is not a member of the
health care team and the guarantee of patient’sa n o n y m -
ity limit this bias (e.g. the patients were not afraid of
being criticized for poor adherence). An additional objec-
tive method (e.g. a count of returned pills) would have
helped to improve the estimation of adherence level.
The enrollment of members of the association could
lead to a biased selection if the survey acceptation is
related to a certain profile of patients that we didn’t
clarified. However, this bias was limited because the
Figure 1 Distribution of patients according to ARVs combination regimens prescribed. (a): 3TC+D4T+NVP; (b): AZT+3TC+EFV; (c): ddi+D4T
+IDV; (d): ddi+D4T+NFV; AZT = zidovudine; 3TC = lamivudine; EFV = efavirenz; D4T = stavudine; NVP = nevirapine; ddi = didanosine; IDV =
indinavir; NFV = nelfinavir.
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EVT health care centres during the period of the study.
The sex ratio in the present study (0.3 with 76.8% of
women) is twice as high compared to that observed by
PNLS [17] and lower than that of South Africa (0.4)
[18], Uganda (0.5) [19] and Senegal (1) [20] cohorts.
Previous reports in Senegal [21], Morocco [22] and
Benin [23] have showed the highest proportion of male.
The patients’ average age is similar to that of PNLS [17]
but less than that reported in Senegal (38 years) [20]
and higher than that observed in Kenya (31.5 years)
[24], Morocco (35.5 years) [22] and in Bothswana (35.6
years) [25].
The whole eligible patients followed the regimens and
the treatment schedule prescribed compared to Diabate
et al’s report in Ivory Cost (76.2% of the patients fol-
lowed their regimen special instructions as against
63.6% who took their medication at the prescribed time)
[26]. However, only 55.6% (n = 55) knew perfectly the
names of ARVs prescribed. This proportion can be
explained by the high proportion of illiterate patients
(19.2%). As previously reported, treatment knowledge
[9] and the cognitive demands related to complexity of
ARVs pharmacotherapy [10,11] have been targeted as
necessary components of adherence.
Standard triple-ARVs combination regimens were pre-
scribed. Four types of ARVs combinations of which two
were based on 2 NRTIs + 1 NNRTI (standard first-line
regimen proposed by WHO) and two on 2 NRTIs + 1
PI (Figure 1) were used compared to 16 different combi-
nations reported by Roux et al [23] in Benin.
About 90% (n = 89) of patients were in 2 NRTIs + 1
NNRTI-based regimens (Figure 1). This proportion is
s i m i l a rt ot h a to b s e r v e db yP N L S - T o g o( 9 0 . 8 % )a f t e ra
national evaluation of ARVs therapy [17]. These regi-
mens available in many other sub-Saharan African
countries [18-20,25,26] are recommended because of
their virological and immunological efficacy. They con-
tribute to improve adherence as there is an available
fixed-dose combination (lamuvidine + stavudine + nevir-
apine) as first-line ARVs regimen. This fixed-dose com-
bination available in other African countries [19,26]
used by 39.4% (n = 39) of patients was highly appre-
ciated because it requires only 2 daily intakes of one
tablet, promoting adherence. However, in this study, we
didn’t observe any statistical difference between treated
groups placed on a fixed-dose combination and treated
groups who received non-fixed-dose combinations.
The average adherence rate was close to that observed
in Senegal (91%) [21], but lower than that reported by
Vriesendorp et al [25] in Botswana (98%) on the basis of
patients’ reports. Several studies showed that 90% to
95% of medication doses should be taken for optimal
virologic suppression and reduction of virologic failure
Table 1 Distribution of patients and median percent of medication doses taken according to the epidemiological
characteristics
Epidemiological characteristics n Median % of doses taken p
Sex Female 28 85.00 0.604
a
Male 9 92.00
Age groups 15-25 years 3 85.00 0.838
b
26-35 years 14 88.50
36-45 years 11 85.00
>45 years 9 92.00
Educational level Non scolarised 8 82.00 0.536
b
Primary level 12 92.00
Secondary level 16 89.00
Universitary level 1 85.00
Triple ARVs therapy received 2 NRTIs + 1 NNRTI 35 85.00 0.638
c
2 NRTIs + 1 PI 2 46.00
Fixed combination 17 85.00 0.626
c
Non fixed combination 20 87.00
ARVs procurement Offered ARVs free of charge 16 85.00 0.269
c
Fixed participation of 11$/month 21 92.00
n: number of patients; a: t-test; b: Kruskal-Wallis one way ANOVA on ranks; c: Mann-Whitney Rank Sum Test
Potchoo et al. BMC Clinical Pharmacology 2010, 10:11
http://www.biomedcentral.com/1472-6904/10/11
Page 4 of 7[27] but according to two studies, a moderate adherence
(80-90%) should lead to a better viral suppression under
more potent regimen including NNRTI [28,29]. Other-
wise, adherence rate of 95% or greater is strongly corre-
lated with CD4 cell count increase, viral load and
morbidity decreases [6]. The proportion of patients with
adherence level of 95% or more (62.62%) is less com-
pared to previous reports in Ivory Cost (74.3%) [26].
Adherence level could be improved if adherence data
sheets updated by prescribers were available allowing
patients follow-up.
Table 1 includes median % of medication doses
taken according to patients’ epidemiological character-
istics. No significant difference have been observed
between the treated groups according to the sex, the
age groups, the educational level, the ARVs regimen
prescribed and the ARVs procurement (p > 0.05). Ours
findings confirm those of previous studies [19,30] con-
cerning these three first factors (excluding younger
age). This lack of difference among treated groups
could be explained by the sensitization of the PLWHA
o nt h er o l eo fA R V st h e r a p ya d h e r e n c eb yt h ea s s o c i a -
tion ‘’Espoir Vie Togo’’.
The existence of tools or methods to promote the
adherence was also reported. In the present study, 43.4%
(n = 43) of patients reported using at least one (69.4%
recognized using a watch/alarm clock to remember the
times of medication intake) compared to 27.9% who sta-
ted being reminded by parents.
Forgetting, travel, cost of treatment and side effects
(Figure 2) have been cited by 43 patients having missed
at least one dose of treatment as the main factors influ-
encing the adherence score and often reported in similar
studies [15,19,24]. Missing drug intake is mainly related
to a state of well being feeling experienced by the
patients, lack of a square meal a day (specific factor in
Africa) [31-33] on which the medication intake is regu-
lated and a feeling of weariness suitable for all long-
term treatment. There is therefore the need to
strengthen advice and information on the consequences
of poor adherence for the patient himself and the threat
for the public health when he does not take his
medications.
Travels were the second main factor of poor adherence.
This factor of non-adherence reveals the problem of the
lack of a pill container containing at least all daily doses.
Figure 2 Distribution of patients (n = 43) according to the factors of poor adherence.
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port and laboratory tests were cited as main obstacles to
optimal adherence. Previous studies have reported the
incidence of payment factor on the rate of loss in HIV-
infected patients’ follow-up and/or adherence in Kenya
[24]. The risk of reduction in terms of loss to follow-up
related to offering ARVs free of charge was 56.6% in
cohorts study [24].
Side effects were the 4th barrier of non adherence
(11.6%). They were collected on the basis of patients’
reports. As a result, we have not considered appropriate
to mention them since they are not validated as such in
contrast to the report of Bhengu et al [34] who con-
ducted a study on the prevalence of symptoms reported
by patients. They have been also reported (including
their severity) as main factors for poor adherence in pre-
vious studies [9,25,35,36]. On the contrary, Bhengu et al
[34] observed no significant relationships between
adherence and the intensity of symptoms. Of the 99
patients included in this study, 89 patients (89.9%)
reported side effects due to ARVs treatment received.
This proportion is higher than that reported in a
national survey by PNLS (31.6% of PLWHA) [17]. In the
present study, five patients (11.6%, n = 43) failed to take
their medication because of side effects. The influence
of these side effects may be lessened by a good patient
information and training to enable them to handle
themselves some minor side effects.
A total of 12 patients (12.1%) stopped or changed one
or more ARVs of the combination regimen for side
effects, inefficiency of treatment and for illness condi-
tions compared to 49.9% reported in the national survey
conducted by PNLS [17].
Overall, a review of the literature shows that the ART-
adherence determinants include institutional, socio-eco-
nomical, psychological and therapeutic factors to take in
account in the management of PLWHA care. However,
the present study didn’t observe any epidemiological
characteristic associated with poor adherence (medica-
tion doses taken less than 95%). To reach optimal
adherence level (100%), our findings suggest the
improvement of PLWHA follow-up with the help of
adherence data sheets, the counseling/information/edu-
cation interventions concerning the virological, biologi-
cal, therapeutic and public health risks of non-
adherence to ARVs therapy.
Conclusion
Our results have shown that the knowledge and the
capacity for adherence to ARVs treatment of PLWHA
in the present study are satisfactory but have not
reached the optimum desirable level. However, these
results reflect the quality of the association “Espoir Vie
Togo” interventions toward PLWHA. They should
encourage the association EVT and all actors involved
in the fight against AIDS to maintain and strengthen
counseling, education, training and information inter-
ventions for PLWHA with a view to overcoming the
potential barriers of poor adherence, given that non-
adherence leading to the development of ARVs-resistant
HIV is a public health concern.
Additional material
Additional file 1: Questionnaire for assessing PLWHA’s knowledge
and adherence level to antiretroviral therapy. The questionnaire
sought the epidemiological characteristics of PLWHA, their knowledge of
ARVs treatment, their adherence level to ART, the factors of poor
adherence, the side effects reported and the prescription of treatment.
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